Health Trials

Stage III NSCLC

2

Review clinical trials related to Stage III NSCLC. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.

Participants needed: 152
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Intergroupe Francophone de Cancerologie ThoraciqueUpdated: Feb 11, 2026Locations: 25
Eligibility criteria

Patients must have signed and dated an IRB/IEC approved written informed consent... [+17]

Immunotherapy or chemotherapy contra-indicated. [+25]

Read more
Status: Recruiting

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

A Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC. Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR, ALK, ROS1, RET).

Participants needed: 30
Trial details
Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: Fondazione Ricerca TraslazionaleUpdated: Dec 4, 2025Locations: 1
Eligibility criteria

Histologically confirmed stage III disease. [+8]

Histology of large cell neuroendocrine carcinoma (LCNEC). [+6]

Read more